Clinical Trials Logo

Clinical Trial Summary

Tuberculosis (TB) is a preventable and curable disease mostly affecting lungs and caused by the bacteria called as Mycobacterium Tuberculosis (MTB). It is estimated that approximately 10 million people are diagnosed with TB every year in the world and 1.7 billion people are infected by MTB and at risk in terms of the development of the disease. Contacted person is the one who shares the same environment with the patient suffering from contagious TB and is exposed to MTB bacilli. Today, the aim of the TB control and prevention programs is to determine the active TB patients and provide cure by healing and also to screen those contacted with the TB patients and determine whether or not they have latent TB infection and treat them and to detect the active cases among the contacts. In the current guidelines, the importance of screening all the contacts of the patients with pulmonary TB and applying a protective treatment for the household in terms of community health care is emphasised. For this reason, it is of prime importance to perform contact screening of the relatives of the TB patients and apply protective treatment. The patients receiving TB and TB protection treatment need to use medicine regularly for at least six months. It is highly important to adherence this period for the success of the treatment. However, it has been reported in the literature that the rate of nonadherence to the TB treatment varies between 20-80% and the nonadherence to the TB treatment is the most serious barrier in the control of the disease. ─░ncomplete treatment may result in long-lasting infection, drug resistance, relapse, and death. In the litareture, it has been stated in the study conducted with the individuals with some chronic diseases that tele-follow-up is effective in providing the self-care agency of patients and the cognitive-social adaptation. It has been reported that some problems emerge especially in the TB patients such as the interruption of treatment, forgetting medication (24.5%), side-effects of drugs, (23.3%), symptomatic recovery (19.5%), failure to know the necessity of completing the life cycle of drugs by most of patients and not receiving adequate training and these problems may be managed more effectively by tele-follow-up. As is known, nurses are involved in all the processes of protecting-promoting the health of the individuals, families and society and their recovery in case of disease. Moreover, providing the protective treatment by performing the required screening for treating TB patients, their follow-up and preventing the development of disease in contacted ones has a vital importance in preventing the spread of TB in the society. Nurses may follow the findings of patients, obtain information about the process, produce information and transmit information with this system (reporting drug changes, performing training follow-up of patients etc.). In the literature, it has been emphasised that tele-mobile nursing services is a cost-effective method since it decreases the hospitalisation rate and period of the TB patients. Accordingly, the main aim of this study is to assess the effect of the training and the telephone follow-up provided by the nurse for the TB patients and contacts on the medication adherence.


Clinical Trial Description

This research was conducted as a randomised, controlled and quasi-experimental study to determine the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence. The population of the study was composed of the patients receiving treatment in a tuberculosis control dispensary between July 2018-July 2019. The sample size was calculated to be 28 in each group through power analysis. Eighty-one TB patients and 90 TB contacts were included in the study. However, 15 TB patients and 3 contacts were excluded since they were transferred to another dispensary and they died. The study was completed with 66 TB patients in the intervention (n= 32) and control groups (n=34) and 87 contacts in the intervention (n= 41) and control groups (n = 46) The TB patients who applied to the dispensary and their contacts were informed about the aim and scope of the study. Then, four groups were formed by using the randomisation menu of the computer program: the intervention and control groups for the TB patients and the intervention and control groups for the contacts. The randomisation was conducted by a statistics specialist who had no contact with the participants. All participants were blinded to the randomisation procedure. However, the researchers were not blinded to the patient groups, due to the nature of the intervention. The interviews were performed by using the face-to-face interview technique in the outpatient clinic. In the first interview, the questionnaire was applied to four groups; TB intervention and TB control group, Contact intervention and Contact control group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05202431
Study type Interventional
Source Tuberculosis Network European Trialsgroup
Contact
Status Completed
Phase N/A
Start date July 1, 2018
Completion date July 30, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Recruiting NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Not yet recruiting NCT05534750 - Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Phase 2
Not yet recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT02774993 - Doxycycline in Human Pulmonary Tuberculosis Phase 2
Completed NCT02536768 - Evaluation of South Africa's National Adherence Strategy N/A
Completed NCT02729571 - Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults Phase 1/Phase 2
Terminated NCT02532036 - MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection Phase 1
Completed NCT01934309 - Do Clinical Decision-support Reminders for Medical Providers Improve the Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya? N/A
Completed NCT01408914 - Trial of High-Dose Rifampin in Patients With TB Phase 2